The anticancer drug ‘Gemzar‘ and schizophrenia drug ‘Zyprexa' Boryung Pharmaceutical had acquired domestic sales and licensing lights of have enjoyed a rebound in sales.

Sales of both drugs had been on a downfall prior to Boryung’s acquisition. Therefore, the analysis is that Boryung’s active portfolio expansion strategy and license acquisition activities have been effective.

◆Gemzar’s sales rise 33% after Boryung’s acquisition...plays a central role in Boryung’s oncology business

According to the pharmaceutical market research institution IQVIA on the 25th, Gemzar raised KRW 19.1 billion in sales last year.

Ge